Unicycive Therapeutics Inc. share price logo

Unicycive Therapeutics Inc.

NASDAQ: UNCY

$5.01

-0.06

(-1.08%)

Live

as on

Unicycive Therapeutics Inc. Stock Performance

as on August 11, 2026 at 4:12 am IST

  • Day's Low

    Day's High

    $4.92
    $5.11
    downward going graph

    1.80%

    Downside

    2.00%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.71
    $8.74
    downward going graph

    25.95%

    Downside

    74.45%

    Upside

    downward going graph

Unicycive Therapeutics Inc. share price movements today

Previous Close
$5.07
Open
$5.08
Volume
702.2K
Day's Low - High
$4.92 - $5.11
52 Week Low - High
$3.71 - $8.74

Unicycive Therapeutics Inc. Historical Returns

1 Month Return
-2.69 %
3 Month Return
-36.15 %
1 Year Return
+ 23.96 %
3 Year Return
-43.67 %
5 Year Return
-82.21 %

Unicycive Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Unicycive Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$138.9M

EPS (TTM)

-1.415

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-29.9M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-163.14%

Unicycive Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Unicycive Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Unicycive Therapeutics Inc. image
Unicycive Therapeutics Inc.
BUY$138.9M-82.21%NA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$44.0B656.45%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$125.7B152.5%28.9135.00%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$80.8B27.54%19.4227.87%0.47000000000000003%

Stock Returns calculator for Unicycive Therapeutics Inc. Stock including INR - Dollar returns

The Unicycive Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Unicycive Therapeutics Inc. investment value today

Current value as on today

₹1,33,156

Returns

₹33,156

(+33.16%)

Returns from Unicycive Therapeutics Inc. Stock

₹22,494 (+22.49%)

Dollar Impact

₹10,662 (+10.66%)

Analyst Recommendation on Unicycive Therapeutics Inc. Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Unicycive Therapeutics Inc.. Average target price of $38.59

Unicycive Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Unicycive Therapeutics Inc..

What analysts predicted

87.02%UPSIDE

Target Price

$38.59

Current Price

$5.01

Analyzed by

11 Analysts

Target

$38.59

Unicycive Therapeutics Inc. target price $38.59, a slight upside of 87.02% compared to current price of $5.01. According to 11 analysts rating.

Indian Investors' Interest in Unicycive Therapeutics Inc. Stock

Search interest for Unicycive Therapeutics Inc. Stock has decreased by -67% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-67% versus previous 30 day period

Unicycive Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
-
-
-
0
-
-
-
-
-
Gross Profit
0
0
-
0
0
0
0
-
0
0
Operating Income
-6
-9
-7
-6
-9
-7
-6
-7
-7
-8
EBITDA
-7
-20
9
-3
-21
0
-6
-5
-14
-12
Interest Expense
0
0
0
0
0
0
0
0
0
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-7
-20
9
-4
-21
0
-6
-6
-14
-12
Income Tax Expense
-10
0
5
-
0
-
-
-
-
-
Net Income
-7
-20
9
-4
-21
0
-6
-6
-14
-12
Net Profit Margin
2877.49%
0.00%
0.00%
0.00%
-3789.61%
0.00%
0.00%
0.00%
0.00%
0.00%

Unicycive Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
0
0
-
-
Gross Profit
-
-
0
0
0
0
0
Operating Income
-1
-2
-8
-18
-20
-32
-29
EBITDA
-2
-2
-8
-17
-30
-36
-25
Interest Expense
0
0
0
0
0
0
0
Depreciation
-
-
0
0
0
0
0
Income Before Tax
-2
-2
-10
-18
-30
-36
-26
Income Tax Expense
0
0
0
0
0
-1
-
Net Income
-2
-2
-10
-18
-30
-36
-26
Net Profit Margin
0.00%
0.00%
0.00%
-1899.47%
-4525.04%
0.00%
0.00%

Unicycive Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-20
9
-4
-21
0
-6
-6
-14
-12
Operating Cash Flow
-6
-6
-9
-6
-8
-8
-5
-8
-6
Investing Cash Flow
0
0
0
0
0
0
0
-12
-5
Financing Cash Flow
45
0
0
0
2
10
26
6
19
Change in Cash
39
-7
-9
-6
-6
2
20
-13
8

Unicycive Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-2
-2
-10
-18
-30
-36
-26
Operating Cash Flow
-1
-1
-5
-15
-18
-28
-31
Investing Cash Flow
0
0
0
0
0
0
-12
Financing Cash Flow
1
1
22
0
27
45
46
Change in Cash
0
0
16
-16
9
16
3

Global Institutional Holdings in Unicycive Therapeutics Inc.

Funds
Holdings
Diadema Partners LP
0.39%
Citadel Advisors Llc
0.86%
XTX Topco Ltd
0.14%
Susquehanna International Group, LLP
0.73%
Renaissance Technologies Corp
0.07%
See all

Unicycive Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 30 June

    Tue, 04:35 PM

    -

    Unicycive receives FDA Complete Response Letter for OLC NDA, citing third-party manufacturing deficiencies without new safety or efficacy concerns.

    Tue, 08:34 PM

    -

    Unicycive stock falls over 46% following FDA's CRL announcement regarding OLC NDA resubmission.

Insights on Unicycive Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -14.66M → -12.82M (in $), with an average increase of 14.4% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, -271.0K → 568.0K (in $), with an average increase of 147.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 588.2% return, outperforming this stock by 631.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 486.1% return, outperforming this stock by 462.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, UNCY stock has moved down by -36.1%

About Unicycive Therapeutics Inc.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
OrganisationUnicycive Therapeutics Inc.
Headquarters1975 West El Camino Real, Mountain View, CA, United States, 94040
IndustryBiotechnology
CEODr. Shalabh K. Gupta M.D., MPA
E-voting on sharesClick here to vote

Key Management of Unicycive Therapeutics Inc.

Name

Title

Mr. Douglas Jermasek M.B.A.

Executive Vice President of Corporate Strategy

Mr. John W. Townsend CPA

Chief Financial Officer

Dr. Shalabh K. Gupta M.D., MPA

Founder, Chairman, CEO & President

Dr. Pramod Gupta Ph.D.

Executive Vice President of Pharmaceutical and Business Operations

FAQs

What is Unicycive Therapeutics Inc. share price today?

Unicycive Therapeutics Inc. share price today is $5.01 as on . Unicycive Therapeutics Inc. share today touched a day high of $5.11 and a low of $4.92.

What is the 52 week high and 52 week low for Unicycive Therapeutics Inc. share?

Unicycive Therapeutics Inc. share touched a 52 week high of $8.74 on and a 52 week low of $3.71 on . Unicycive Therapeutics Inc. stock price today i.e. is trending at $5.01,which is 42.68% down from its 52 week high and 35.04% up from its 52 week low.

What is Unicycive Therapeutics Inc.'s market capitalisation today?

Unicycive Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Unicycive Therapeutics Inc. Stock (UNCY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Unicycive Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Unicycive Therapeutics Inc. Shares that will get you 0.2994 shares as per Unicycive Therapeutics Inc. share price of $5.01 per share as on August 10, 2026 at 10:42 pm IST.

What is the minimum amount required to buy Unicycive Therapeutics Inc. Stock (UNCY) from India?

Indian investors can start investing in Unicycive Therapeutics Inc. (UNCY) shares with as little as ₹95.29 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.90 in Unicycive Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Unicycive Therapeutics Inc. share’s latest price of $5.01 as on August 10, 2026 at 10:42 pm IST, you will get 1.9960 shares of Unicycive Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Unicycive Therapeutics Inc. has given to Indian investors in the last 5 years?

Unicycive Therapeutics Inc. stock has given -82.21% share price returns and 27.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?